Pharmacokinetics of cisplatin in semi-closed hyperthermic peritoneal perfusion (HPP) for treatment of peritoneal carcinomatosis

Anticancer Research

Volumn 24, Issue 3 B, 2004, Pages 2041-2045

  Cattel, Luigi ^a   De Simone, Michele ^b,c   Passera, Roberto ^a   Verlengo, Maria Cristina ^a   Delprino, Laura ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c SAN GIUSEPPE HOSPITAL   (Italy)

Author keywords

Cisplatin; Hyperthermia; Intraperitoneal perfusion

Indexed keywords

CISPLATIN; DOXORUBICIN; MITOMYCIN; RECOMBINANT TUMOR NECROSIS FACTOR;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOOD SAMPLING; BONE MARROW SUPPRESSION; CANCER CYTOREDUCTION; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; DIARRHEA; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; EVIDENCE BASED MEDICINE; FEVER; FLOW RATE; HUMAN; HYPERTHERMIC PERITONEAL PERFUSION; HYPERTHERMIC THERAPY; LUNG TOXICITY; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; PRIORITY JOURNAL; SEMI CLOSED HYPERTHERMIC PERITONEAL PERFUSION; SIDE EFFECT; SURGICAL TECHNIQUE; TACHYCARDIA; ULTRAFILTRATION; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CISPLATIN; COMBINED MODALITY THERAPY; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; PERITONEAL NEOPLASMS; PERITONEUM;

EID: 3242656517     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Alexander HR, Buell JF and Fraker DL: Rationale and clinical status of continuous hyperthermic peritoneal perfusion (CHPP) for the treatment of peritoneal carcinomatosis. In: DeVita V, Hellman S, Rosenberg S: Principles and Practices of Oncology Updates. 9th ed. Philadelphia: Lipincott JB, 1-9, 1995.
2. Sayag AC, Gilly FN, Carry PY, Perdrix JP, Panteix G, Brachet A, Banssillon V and Braillon G: Intraoperative chemohyperthermia in the management of digestive cancers. Oncology 50: 333-337, 1993.
3. Markman M: Intraperitoneal cisplatin chemotherapy in the management of ovarian carcinoma. Sem Oncol 16: 79-82, 1989.
4. Barlogie B, Corry PM and Drewinko B: In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res 40: 1165-1168, 1980.
5. Zakris EL, Dewhirst MW, Riviere JE, Hoopes PJ, Page RL and Oleson JR: Pharmacokinetics and toxicity of intraperitoneal cisplatin combined with regional hyperthermia. J Clin Oncol 5: 1613-1620, 1987.
6. Bartlett DL, Buell JF, Libutti SK, Reed E, Lee KB, Figg WD, Venzon DJ and Alexander HR: A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer 83: 1251-1261, 1998.
7. Stephens AD, Belliveau JF and Sugarbaker PH: Intraoperative hyperthermic lavage with cisplatin for peritoneal carcinomatosis. and sarcomatosis. In: Sugarbaker PH: Peritoneal Carcinomatosis: Drugs and Diseases. Boston: Kluver Ed., 15-30, 1996.
8. Ma GY, Bartlett DL, Reed E, Figg WD, Lush RM, Lee KB, Libutti SK and Alexander HR: Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma. Cancer J Sci Am 3: 174-179, 1997.
9. van de Vaart PJM, van der Vange N, Zoetmulder FAN, van Goethem AR, van Tellingen O, ten Bokkel Huinink WW, Beijnen JH, Bartelink H and Begg AC: Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 34: 148-154, 1998.
10. Cho HK, Lush RM, Bartlett DL, Alexander HR, Wu PC, Libutti SK, Lee KB, Venzon DJ, Bauer KS, Reed E and Figg WD: Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis. J Clin Pharmacol 39: 394-401, 1999.
11. Rossi CR, Foletto M, Mocellin S, Pilati P, De Simone M, Deraco M, Cavaliere F, Palatini P, Guasti F, Scalerta R and Lise M: Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase 1 study. Cancer 94: 492-499, 2002.
12. Go RS and Adjei AA: Review of comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17: 409-422, 1999.
13. De Simone M, Barone R, Vaira M, Aghemo B, Mioli PR, Franco C, Scuderi S, Costamagna D and Dei Poli M: Semi-closed Hyperthermic-Antiblastic Peritoneal Perfusion (HAPP) in the treatment of peritoneal carcinosis. J Surg Oncol 82: 138-140, 2003.
14. van Warmerdam LJC, van Tellingen O, Maes RAA and Beijnen JH: Validated method for the determination of carboplatin in biological fluids by Zeeman atomic absorption spectrometry. Fresenius J Anal Chem 351: 777-781, 1995.
15. Pera MF Jr and Harder HC: Analysis for platinum in biological material by flameless atomic absorption spectrometry. Clin Chem 23: 1245-1249, 1977.
16. Chu DZ, Lang NP, Thompson C, Osteen PK and Westbrook KC: Peritoneal carcinomatosis in nongynecologic malignancies: a prospective study of prognosis factors. Cancer 63: 364-367, 1989.
17. Belt RJ, Himmelstein KJ, Patton TF, Bannister SJ, Sternson LA and Repta AJ: Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum (II). Cancer Treat Rep 63: 1515-1521, 1979.
18. Vermorken JB, van der Vijgh WJF, Klein I, Hart AAM, Gall HE and Pinedo HM: Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. Cancer Treat Rep 68: 505-513, 1984.